Events subsequent to quarter end include $40.25 million financing and Phase 1 clinical trial VANCOUVER, BC, April 29, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its second quarter financial results for the three months ended…


Previous articleOp-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs Escitalopram for Depression
Next articlePTSF57 – New Compounds, Psychedelic Business, and Neurogenesis